Consensus statement: medical management of acromegaly.
In November 2003, the Pituitary Society and the European Neuroendocrine Association sponsored a consensus workshop in Seville to address challenging issues in the medical management of acromegaly. Participants comprised 70 endocrinologists and neurosurgeons with international expertise in managing patients with acromegaly. All participants participated in the workshop proceedings, and the final document written by the scientific committee reflects the consensus opinion of the interactive deliberations. The meeting was supported by an unrestricted educational grant from Ipsen. No pharmaceutical representatives participated in the program planning or in the scientific deliberations.
Melmed
S
S
Cedar-Sinai Research Institute, UCLA School of Medicine, Los Angeles, USA.
Casanueva
F
F
Cavagnini
F
F
Chanson
P
P
Frohman
L A
LA
Gaillard
R
R
Ghigo
E
E
Ho
K
K
Jaquet
P
P
Kleinberg
D
D
Lamberts
S
S
Laws
E
E
Lombardi
G
G
Sheppard
M C
MC
Thorner
M
M
Vance
M L
ML
Wass
J A H
JA
Giustina
A
A
D000172:Acromegaly / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D018491:Dopamine Agonists / Q000627:therapeutic use; D005260:Female; D019382:Human Growth Hormone / Q000031:analogs & derivatives / Q000097:blood / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use
D018491:Dopamine Agonists; D019382:Human Growth Hormone; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; C406545:pegvisomant